Evidence map›Paper›PMID 41613311›Full record

ArticleFrontiers in medicine2025

A retrospective single-center cohort study of major subtypes of primary glomerular diseases (MN, IgAN, and MCD): clinical characteristics, prognostic outcomes, and risk factors.

Wei Zhang, Yemei Dai, Wei Zhang, Yuze Wang, Lihua Wang

Abstract read
In one paragraph

Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Wei Zhang *Department of Nephrology, Shanxi Medical University Second Hospital, Taiyuan, China.
Yemei Dai *Department of Nephrology, Shanxi Medical University Second Hospital, Taiyuan, China.
Wei ZhangDepartment of Nephrology, Changzhi Medical College Affiliated Heji Hospital, Changzhi, China.
Yuze WangCollege of Computer Science and Cyber Security (Oxford Brookes College), Chengdu University of Technology, Chengdu, China.
Lihua WangDepartment of Nephrology, Shanxi Medical University Second Hospital, Taiyuan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: This study aims to investigate patients with the three major types of primary glomerular diseases who underwent kidney biopsy at our center, with the objectives of characterizing their clinical phenotypes and pathological features, and identifying risk factors for clinical outcome events. Methods: Between January 2013 and December 2023, consecutive patients diagnosed with membranous nephropathy (MN), immunoglobulin A nephropathy (IgAN), and minimal change disease (MCD) by kidney biopsy were included in this retrospective follow-up study. Outcome measures included proteinuria remission and kidney disease progression events. Multivariate-adjusted Cox proportional hazards models were utilized. Results: A total of 608 patients were included in the follow-up cohort, comprising 438 with MN, 110 with IgAN, and 60 with MCD. Clinical remission was achieved in 481 (79.1%) patients, including 333 (54.8%) with complete remission (CR) and 148 (24.3%) with partial remission (PR). Kidney disease progression occurred in 79 (13.0%) patients. After balancing for baseline data and pathological diagnoses in relation to different outcomes, 24-h urinary total protein (24 h-UTP; ≥ 3.5 g/d vs. < 3.5 g/d: HR 1.35, 95% CI 1.10-1.64, Conclusion: Undertaken at a single center, this study outlines the spectrum of current treatments, clinical outcomes, and factors influencing these outcomes among patients newly diagnosed with the three principal glomerular diseases through kidney biopsy.

Indexed as

chronic kidney diseasesglomerulonephritisimmunoglobulin A nephropathyimmunosuppressive therapykidney disease progressionmembranous nephropathyminimal change diseasetraditional chinese medicine

Identifiers

PMID41613311
PMCPMC12846976

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.